Wall Street analysts support Abbott’s planned $890m acquisition of Cardiovascular Systems (CSI) as a relatively inexpensive way for Abbott to expand its presence in the peripheral intervention market.
Abbott Buys CSI To Add Peripheral And Coronary Atherectomy Technologies
CSI markets minimally invasive devices to remove vascular plaques and has a full pipeline of complementary vascular intervention technologies. Abbott expects CSI’s products to complement its existing coronary intervention business and expand its presence in the peripheral market.
